Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Cellectis SA (CMVLF) Drug Pipeline

10 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Clls52, Ucart20x22B-Cell Non-Hodgkin Lymphoma (B-Nhl)phase1AndPhase2RecruitingStudy Evaluating UCART20x22 in B-Cell Non-Hodgkin LymphomaOct 25, 2022
Ucart22, Clls52B-Cell Acute Lymphoblastic Leukemiaphase1AndPhase2RecruitingPhase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)Nov 01, 2019―
Ucartcs1aRelapsed/Refractory Multiple MyelomaPhase ITerminatedStudy Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)Oct 25, 2019―
Ucart123Acute Myeloid LeukaemiaPhase IWithdrawnPhase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid LeukemiaSep 25, 2019―
Ucart123Blastic Plasmacytoid Dendritic Cell Neoplasm (Bpdcn)Phase ITerminatedStudy to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCNJun 14, 2017―
Ucart123v1.2Relapsed/Refractory Acute Myeloid LeukemiaPhase IActive Not RecruitingStudy Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaJun 14, 2017―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cellectis SA (CMVLF) have in its pipeline
Cellectis SA CMVLF is currently developing the following drugs: Clls52, Ucart20x22, Ucart22, Clls52, Ucartcs1a, Ucart123, Ucart123v1.2. These drug candidates are in various stages of clinical development as the company works toward FDA approval.